By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo

TheMediTary.Com

Medical Information, Documents, News - TheMediTary.Com

  • Home
  • News
  • Drugs
  • Drugs A-Z
  • Medical Answers
  • About Us
  • Contact
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo
Search Drugs
  • Drugs
    • Latest Drugs
    • Drugs A-Z
    • Medical Answers
  • News
    • FDA Alerts
    • Medical News
    • Health
    • Consumer Updates
    • Children's Health
  • More TheMediTary.Com
    • About Us
    • Contact
Follow US
Home > Drugs > Second generation cephalosporins > Cefoxitin > Cefoxitin Dosage
Second generation cephalosporins
https://themeditary.com/dosage-information/cefoxitin-dosage-10050.html

Cefoxitin Dosage

Drug Detail:Cefoxitin (Cefoxitin [ sef-ox-i-tin ])

Drug Class: Second generation cephalosporins

Contents
Uses Warnings Before Taking Dosage Side effects Interactions

Usual Adult Dose for Aspiration Pneumonia

Uncomplicated infections (bacteremia absent/unlikely): 1 gram IV every 6 to 8 hours
Moderately severe to severe infections: 1 gram IV every 4 hours OR 2 grams IV every 6 to 8 hours
Infections needing high-doses: 2 grams IV every 4 hours OR 3 grams IV every 6 hours
Duration of therapy: At least 10 days (group A beta-hemolytic streptococcal infections)

Comments:

  • This drug may be given via IV injection over 3 to 5 minutes or via IV infusion.
  • Uncomplicated infections included cutaneous infections, pneumonia, and urinary tract infections.
  • High-dose infections include gas gangrene.
  • Surgical drainage should be performed in infections involving collections of pus.

Uses:
  • Treatment of bone and joint infections caused by Staphylococcus aureus (including penicillinase-producing strains)
  • Treatment of intraabdominal infections (e.g., intraabdominal abscess, peritonitis) caused by Bacteroides species (including Bacteroides fragilis), Clostridium species, Escherichia coli, and Klebsiella species
  • Treatment of lower respiratory tract infections (e.g., lung abscesses, pneumonia) caused by Bacteroides species, Escherichia coli, Haemophilus influenzae, Klebsiella species, other streptococci (excluding enterococci, e.g., Enterococcus faecalis/Streptococcus faecalis), S aureus (including penicillinase-producing strains), and Streptococcus pneumoniae
  • Treatment of skin and structure infections cause by Bacteroides species (including B fragilis), Clostridium species, E coli, Klebsiella species, Peptococcus niger, Peptostreptococcus species, Proteus mirabilis, S aureus (including penicillinase-producing strains), Staphylococcus epidermidis, Streptococcus pyogenes and other streptococci (excluding enterococci, e.g., E faecalis/S faecalis)
  • Treatment of urinary tract infections caused by E coli, Klebsiella species, Morganella morganii, P mirabilis, Proteus vulgaris, and Providencia species (including Providencia rettgeri)

Infectious Diseases Society of America (IDSA) Recommendations:
1 gram IV every 6 to 8 hours

Duration of therapy:
  • Bone/joint infection without residual infected tissue (e.g., postamputation): 2 to 5 days)
  • Moderate diabetic foot infection, including residual infected soft tissue (soft tissue only): 1 to 3 weeks
  • Severe diabetic foot infection (soft tissue only): 2 to 4 weeks
  • Residual infected, but viable, bone: 4 to 6 weeks
  • No surgery or postoperative residual dead bone: 3 months or longer

Comment: Patients with diabetic foot infections should be started on parenteral treatment and should be switched to oral formulations when possible.

Uses:
  • Alternative treatment of infections following animal bites
  • Preemptive antimicrobial therapy to prevent infection in dog or cat bites
  • Alternative treatment for infected animal bite-related wounds caused by Pasteurella multocida
  • Empiric treatment of moderate or severe diabetic foot infections caused by methicillin-susceptible S aureus (MSSA), other Streptococcus species, Enterobacteriaceae, and/or obligate anaerobes

Usual Adult Dose for Intraabdominal Infection

Uncomplicated infections (bacteremia absent/unlikely): 1 gram IV every 6 to 8 hours
Moderately severe to severe infections: 1 gram IV every 4 hours OR 2 grams IV every 6 to 8 hours
Infections needing high-doses: 2 grams IV every 4 hours OR 3 grams IV every 6 hours
Duration of therapy: At least 10 days (group A beta-hemolytic streptococcal infections)

Comments:

  • This drug may be given via IV injection over 3 to 5 minutes or via IV infusion.
  • Uncomplicated infections included cutaneous infections, pneumonia, and urinary tract infections.
  • High-dose infections include gas gangrene.
  • Surgical drainage should be performed in infections involving collections of pus.

Uses:
  • Treatment of bone and joint infections caused by Staphylococcus aureus (including penicillinase-producing strains)
  • Treatment of intraabdominal infections (e.g., intraabdominal abscess, peritonitis) caused by Bacteroides species (including Bacteroides fragilis), Clostridium species, Escherichia coli, and Klebsiella species
  • Treatment of lower respiratory tract infections (e.g., lung abscesses, pneumonia) caused by Bacteroides species, Escherichia coli, Haemophilus influenzae, Klebsiella species, other streptococci (excluding enterococci, e.g., Enterococcus faecalis/Streptococcus faecalis), S aureus (including penicillinase-producing strains), and Streptococcus pneumoniae
  • Treatment of skin and structure infections cause by Bacteroides species (including B fragilis), Clostridium species, E coli, Klebsiella species, Peptococcus niger, Peptostreptococcus species, Proteus mirabilis, S aureus (including penicillinase-producing strains), Staphylococcus epidermidis, Streptococcus pyogenes and other streptococci (excluding enterococci, e.g., E faecalis/S faecalis)
  • Treatment of urinary tract infections caused by E coli, Klebsiella species, Morganella morganii, P mirabilis, Proteus vulgaris, and Providencia species (including Providencia rettgeri)

Infectious Diseases Society of America (IDSA) Recommendations:
1 gram IV every 6 to 8 hours

Duration of therapy:
  • Bone/joint infection without residual infected tissue (e.g., postamputation): 2 to 5 days)
  • Moderate diabetic foot infection, including residual infected soft tissue (soft tissue only): 1 to 3 weeks
  • Severe diabetic foot infection (soft tissue only): 2 to 4 weeks
  • Residual infected, but viable, bone: 4 to 6 weeks
  • No surgery or postoperative residual dead bone: 3 months or longer

Comment: Patients with diabetic foot infections should be started on parenteral treatment and should be switched to oral formulations when possible.

Uses:
  • Alternative treatment of infections following animal bites
  • Preemptive antimicrobial therapy to prevent infection in dog or cat bites
  • Alternative treatment for infected animal bite-related wounds caused by Pasteurella multocida
  • Empiric treatment of moderate or severe diabetic foot infections caused by methicillin-susceptible S aureus (MSSA), other Streptococcus species, Enterobacteriaceae, and/or obligate anaerobes

Usual Adult Dose for Joint Infection

Uncomplicated infections (bacteremia absent/unlikely): 1 gram IV every 6 to 8 hours
Moderately severe to severe infections: 1 gram IV every 4 hours OR 2 grams IV every 6 to 8 hours
Infections needing high-doses: 2 grams IV every 4 hours OR 3 grams IV every 6 hours
Duration of therapy: At least 10 days (group A beta-hemolytic streptococcal infections)

Comments:

  • This drug may be given via IV injection over 3 to 5 minutes or via IV infusion.
  • Uncomplicated infections included cutaneous infections, pneumonia, and urinary tract infections.
  • High-dose infections include gas gangrene.
  • Surgical drainage should be performed in infections involving collections of pus.

Uses:
  • Treatment of bone and joint infections caused by Staphylococcus aureus (including penicillinase-producing strains)
  • Treatment of intraabdominal infections (e.g., intraabdominal abscess, peritonitis) caused by Bacteroides species (including Bacteroides fragilis), Clostridium species, Escherichia coli, and Klebsiella species
  • Treatment of lower respiratory tract infections (e.g., lung abscesses, pneumonia) caused by Bacteroides species, Escherichia coli, Haemophilus influenzae, Klebsiella species, other streptococci (excluding enterococci, e.g., Enterococcus faecalis/Streptococcus faecalis), S aureus (including penicillinase-producing strains), and Streptococcus pneumoniae
  • Treatment of skin and structure infections cause by Bacteroides species (including B fragilis), Clostridium species, E coli, Klebsiella species, Peptococcus niger, Peptostreptococcus species, Proteus mirabilis, S aureus (including penicillinase-producing strains), Staphylococcus epidermidis, Streptococcus pyogenes and other streptococci (excluding enterococci, e.g., E faecalis/S faecalis)
  • Treatment of urinary tract infections caused by E coli, Klebsiella species, Morganella morganii, P mirabilis, Proteus vulgaris, and Providencia species (including Providencia rettgeri)

Infectious Diseases Society of America (IDSA) Recommendations:
1 gram IV every 6 to 8 hours

Duration of therapy:
  • Bone/joint infection without residual infected tissue (e.g., postamputation): 2 to 5 days)
  • Moderate diabetic foot infection, including residual infected soft tissue (soft tissue only): 1 to 3 weeks
  • Severe diabetic foot infection (soft tissue only): 2 to 4 weeks
  • Residual infected, but viable, bone: 4 to 6 weeks
  • No surgery or postoperative residual dead bone: 3 months or longer

Comment: Patients with diabetic foot infections should be started on parenteral treatment and should be switched to oral formulations when possible.

Uses:
  • Alternative treatment of infections following animal bites
  • Preemptive antimicrobial therapy to prevent infection in dog or cat bites
  • Alternative treatment for infected animal bite-related wounds caused by Pasteurella multocida
  • Empiric treatment of moderate or severe diabetic foot infections caused by methicillin-susceptible S aureus (MSSA), other Streptococcus species, Enterobacteriaceae, and/or obligate anaerobes

Usual Adult Dose for Osteomyelitis

Uncomplicated infections (bacteremia absent/unlikely): 1 gram IV every 6 to 8 hours
Moderately severe to severe infections: 1 gram IV every 4 hours OR 2 grams IV every 6 to 8 hours
Infections needing high-doses: 2 grams IV every 4 hours OR 3 grams IV every 6 hours
Duration of therapy: At least 10 days (group A beta-hemolytic streptococcal infections)

Comments:

  • This drug may be given via IV injection over 3 to 5 minutes or via IV infusion.
  • Uncomplicated infections included cutaneous infections, pneumonia, and urinary tract infections.
  • High-dose infections include gas gangrene.
  • Surgical drainage should be performed in infections involving collections of pus.

Uses:
  • Treatment of bone and joint infections caused by Staphylococcus aureus (including penicillinase-producing strains)
  • Treatment of intraabdominal infections (e.g., intraabdominal abscess, peritonitis) caused by Bacteroides species (including Bacteroides fragilis), Clostridium species, Escherichia coli, and Klebsiella species
  • Treatment of lower respiratory tract infections (e.g., lung abscesses, pneumonia) caused by Bacteroides species, Escherichia coli, Haemophilus influenzae, Klebsiella species, other streptococci (excluding enterococci, e.g., Enterococcus faecalis/Streptococcus faecalis), S aureus (including penicillinase-producing strains), and Streptococcus pneumoniae
  • Treatment of skin and structure infections cause by Bacteroides species (including B fragilis), Clostridium species, E coli, Klebsiella species, Peptococcus niger, Peptostreptococcus species, Proteus mirabilis, S aureus (including penicillinase-producing strains), Staphylococcus epidermidis, Streptococcus pyogenes and other streptococci (excluding enterococci, e.g., E faecalis/S faecalis)
  • Treatment of urinary tract infections caused by E coli, Klebsiella species, Morganella morganii, P mirabilis, Proteus vulgaris, and Providencia species (including Providencia rettgeri)

Infectious Diseases Society of America (IDSA) Recommendations:
1 gram IV every 6 to 8 hours

Duration of therapy:
  • Bone/joint infection without residual infected tissue (e.g., postamputation): 2 to 5 days)
  • Moderate diabetic foot infection, including residual infected soft tissue (soft tissue only): 1 to 3 weeks
  • Severe diabetic foot infection (soft tissue only): 2 to 4 weeks
  • Residual infected, but viable, bone: 4 to 6 weeks
  • No surgery or postoperative residual dead bone: 3 months or longer

Comment: Patients with diabetic foot infections should be started on parenteral treatment and should be switched to oral formulations when possible.

Uses:
  • Alternative treatment of infections following animal bites
  • Preemptive antimicrobial therapy to prevent infection in dog or cat bites
  • Alternative treatment for infected animal bite-related wounds caused by Pasteurella multocida
  • Empiric treatment of moderate or severe diabetic foot infections caused by methicillin-susceptible S aureus (MSSA), other Streptococcus species, Enterobacteriaceae, and/or obligate anaerobes

Usual Adult Dose for Peritonitis

Uncomplicated infections (bacteremia absent/unlikely): 1 gram IV every 6 to 8 hours
Moderately severe to severe infections: 1 gram IV every 4 hours OR 2 grams IV every 6 to 8 hours
Infections needing high-doses: 2 grams IV every 4 hours OR 3 grams IV every 6 hours
Duration of therapy: At least 10 days (group A beta-hemolytic streptococcal infections)

Comments:

  • This drug may be given via IV injection over 3 to 5 minutes or via IV infusion.
  • Uncomplicated infections included cutaneous infections, pneumonia, and urinary tract infections.
  • High-dose infections include gas gangrene.
  • Surgical drainage should be performed in infections involving collections of pus.

Uses:
  • Treatment of bone and joint infections caused by Staphylococcus aureus (including penicillinase-producing strains)
  • Treatment of intraabdominal infections (e.g., intraabdominal abscess, peritonitis) caused by Bacteroides species (including Bacteroides fragilis), Clostridium species, Escherichia coli, and Klebsiella species
  • Treatment of lower respiratory tract infections (e.g., lung abscesses, pneumonia) caused by Bacteroides species, Escherichia coli, Haemophilus influenzae, Klebsiella species, other streptococci (excluding enterococci, e.g., Enterococcus faecalis/Streptococcus faecalis), S aureus (including penicillinase-producing strains), and Streptococcus pneumoniae
  • Treatment of skin and structure infections cause by Bacteroides species (including B fragilis), Clostridium species, E coli, Klebsiella species, Peptococcus niger, Peptostreptococcus species, Proteus mirabilis, S aureus (including penicillinase-producing strains), Staphylococcus epidermidis, Streptococcus pyogenes and other streptococci (excluding enterococci, e.g., E faecalis/S faecalis)
  • Treatment of urinary tract infections caused by E coli, Klebsiella species, Morganella morganii, P mirabilis, Proteus vulgaris, and Providencia species (including Providencia rettgeri)

Infectious Diseases Society of America (IDSA) Recommendations:
1 gram IV every 6 to 8 hours

Duration of therapy:
  • Bone/joint infection without residual infected tissue (e.g., postamputation): 2 to 5 days)
  • Moderate diabetic foot infection, including residual infected soft tissue (soft tissue only): 1 to 3 weeks
  • Severe diabetic foot infection (soft tissue only): 2 to 4 weeks
  • Residual infected, but viable, bone: 4 to 6 weeks
  • No surgery or postoperative residual dead bone: 3 months or longer

Comment: Patients with diabetic foot infections should be started on parenteral treatment and should be switched to oral formulations when possible.

Uses:
  • Alternative treatment of infections following animal bites
  • Preemptive antimicrobial therapy to prevent infection in dog or cat bites
  • Alternative treatment for infected animal bite-related wounds caused by Pasteurella multocida
  • Empiric treatment of moderate or severe diabetic foot infections caused by methicillin-susceptible S aureus (MSSA), other Streptococcus species, Enterobacteriaceae, and/or obligate anaerobes

Usual Adult Dose for Pneumonia

Uncomplicated infections (bacteremia absent/unlikely): 1 gram IV every 6 to 8 hours
Moderately severe to severe infections: 1 gram IV every 4 hours OR 2 grams IV every 6 to 8 hours
Infections needing high-doses: 2 grams IV every 4 hours OR 3 grams IV every 6 hours
Duration of therapy: At least 10 days (group A beta-hemolytic streptococcal infections)

Comments:

  • This drug may be given via IV injection over 3 to 5 minutes or via IV infusion.
  • Uncomplicated infections included cutaneous infections, pneumonia, and urinary tract infections.
  • High-dose infections include gas gangrene.
  • Surgical drainage should be performed in infections involving collections of pus.

Uses:
  • Treatment of bone and joint infections caused by Staphylococcus aureus (including penicillinase-producing strains)
  • Treatment of intraabdominal infections (e.g., intraabdominal abscess, peritonitis) caused by Bacteroides species (including Bacteroides fragilis), Clostridium species, Escherichia coli, and Klebsiella species
  • Treatment of lower respiratory tract infections (e.g., lung abscesses, pneumonia) caused by Bacteroides species, Escherichia coli, Haemophilus influenzae, Klebsiella species, other streptococci (excluding enterococci, e.g., Enterococcus faecalis/Streptococcus faecalis), S aureus (including penicillinase-producing strains), and Streptococcus pneumoniae
  • Treatment of skin and structure infections cause by Bacteroides species (including B fragilis), Clostridium species, E coli, Klebsiella species, Peptococcus niger, Peptostreptococcus species, Proteus mirabilis, S aureus (including penicillinase-producing strains), Staphylococcus epidermidis, Streptococcus pyogenes and other streptococci (excluding enterococci, e.g., E faecalis/S faecalis)
  • Treatment of urinary tract infections caused by E coli, Klebsiella species, Morganella morganii, P mirabilis, Proteus vulgaris, and Providencia species (including Providencia rettgeri)

Infectious Diseases Society of America (IDSA) Recommendations:
1 gram IV every 6 to 8 hours

Duration of therapy:
  • Bone/joint infection without residual infected tissue (e.g., postamputation): 2 to 5 days)
  • Moderate diabetic foot infection, including residual infected soft tissue (soft tissue only): 1 to 3 weeks
  • Severe diabetic foot infection (soft tissue only): 2 to 4 weeks
  • Residual infected, but viable, bone: 4 to 6 weeks
  • No surgery or postoperative residual dead bone: 3 months or longer

Comment: Patients with diabetic foot infections should be started on parenteral treatment and should be switched to oral formulations when possible.

Uses:
  • Alternative treatment of infections following animal bites
  • Preemptive antimicrobial therapy to prevent infection in dog or cat bites
  • Alternative treatment for infected animal bite-related wounds caused by Pasteurella multocida
  • Empiric treatment of moderate or severe diabetic foot infections caused by methicillin-susceptible S aureus (MSSA), other Streptococcus species, Enterobacteriaceae, and/or obligate anaerobes

Usual Adult Dose for Bacterial Infection

Uncomplicated infections (bacteremia absent/unlikely): 1 gram IV every 6 to 8 hours
Moderately severe to severe infections: 1 gram IV every 4 hours OR 2 grams IV every 6 to 8 hours
Infections needing high-doses: 2 grams IV every 4 hours OR 3 grams IV every 6 hours
Duration of therapy: At least 10 days (group A beta-hemolytic streptococcal infections)

Comments:

  • This drug may be given via IV injection over 3 to 5 minutes or via IV infusion.
  • Uncomplicated infections included cutaneous infections, pneumonia, and urinary tract infections.
  • High-dose infections include gas gangrene.
  • Surgical drainage should be performed in infections involving collections of pus.

Uses:
  • Treatment of bone and joint infections caused by Staphylococcus aureus (including penicillinase-producing strains)
  • Treatment of intraabdominal infections (e.g., intraabdominal abscess, peritonitis) caused by Bacteroides species (including Bacteroides fragilis), Clostridium species, Escherichia coli, and Klebsiella species
  • Treatment of lower respiratory tract infections (e.g., lung abscesses, pneumonia) caused by Bacteroides species, Escherichia coli, Haemophilus influenzae, Klebsiella species, other streptococci (excluding enterococci, e.g., Enterococcus faecalis/Streptococcus faecalis), S aureus (including penicillinase-producing strains), and Streptococcus pneumoniae
  • Treatment of skin and structure infections cause by Bacteroides species (including B fragilis), Clostridium species, E coli, Klebsiella species, Peptococcus niger, Peptostreptococcus species, Proteus mirabilis, S aureus (including penicillinase-producing strains), Staphylococcus epidermidis, Streptococcus pyogenes and other streptococci (excluding enterococci, e.g., E faecalis/S faecalis)
  • Treatment of urinary tract infections caused by E coli, Klebsiella species, Morganella morganii, P mirabilis, Proteus vulgaris, and Providencia species (including Providencia rettgeri)

Infectious Diseases Society of America (IDSA) Recommendations:
1 gram IV every 6 to 8 hours

Duration of therapy:
  • Bone/joint infection without residual infected tissue (e.g., postamputation): 2 to 5 days)
  • Moderate diabetic foot infection, including residual infected soft tissue (soft tissue only): 1 to 3 weeks
  • Severe diabetic foot infection (soft tissue only): 2 to 4 weeks
  • Residual infected, but viable, bone: 4 to 6 weeks
  • No surgery or postoperative residual dead bone: 3 months or longer

Comment: Patients with diabetic foot infections should be started on parenteral treatment and should be switched to oral formulations when possible.

Uses:
  • Alternative treatment of infections following animal bites
  • Preemptive antimicrobial therapy to prevent infection in dog or cat bites
  • Alternative treatment for infected animal bite-related wounds caused by Pasteurella multocida
  • Empiric treatment of moderate or severe diabetic foot infections caused by methicillin-susceptible S aureus (MSSA), other Streptococcus species, Enterobacteriaceae, and/or obligate anaerobes

Usual Adult Dose for Urinary Tract Infection

Uncomplicated infections (bacteremia absent/unlikely): 1 gram IV every 6 to 8 hours
Moderately severe to severe infections: 1 gram IV every 4 hours OR 2 grams IV every 6 to 8 hours
Infections needing high-doses: 2 grams IV every 4 hours OR 3 grams IV every 6 hours
Duration of therapy: At least 10 days (group A beta-hemolytic streptococcal infections)

Comments:

  • This drug may be given via IV injection over 3 to 5 minutes or via IV infusion.
  • Uncomplicated infections included cutaneous infections, pneumonia, and urinary tract infections.
  • High-dose infections include gas gangrene.
  • Surgical drainage should be performed in infections involving collections of pus.

Uses:
  • Treatment of bone and joint infections caused by Staphylococcus aureus (including penicillinase-producing strains)
  • Treatment of intraabdominal infections (e.g., intraabdominal abscess, peritonitis) caused by Bacteroides species (including Bacteroides fragilis), Clostridium species, Escherichia coli, and Klebsiella species
  • Treatment of lower respiratory tract infections (e.g., lung abscesses, pneumonia) caused by Bacteroides species, Escherichia coli, Haemophilus influenzae, Klebsiella species, other streptococci (excluding enterococci, e.g., Enterococcus faecalis/Streptococcus faecalis), S aureus (including penicillinase-producing strains), and Streptococcus pneumoniae
  • Treatment of skin and structure infections cause by Bacteroides species (including B fragilis), Clostridium species, E coli, Klebsiella species, Peptococcus niger, Peptostreptococcus species, Proteus mirabilis, S aureus (including penicillinase-producing strains), Staphylococcus epidermidis, Streptococcus pyogenes and other streptococci (excluding enterococci, e.g., E faecalis/S faecalis)
  • Treatment of urinary tract infections caused by E coli, Klebsiella species, Morganella morganii, P mirabilis, Proteus vulgaris, and Providencia species (including Providencia rettgeri)

Infectious Diseases Society of America (IDSA) Recommendations:
1 gram IV every 6 to 8 hours

Duration of therapy:
  • Bone/joint infection without residual infected tissue (e.g., postamputation): 2 to 5 days)
  • Moderate diabetic foot infection, including residual infected soft tissue (soft tissue only): 1 to 3 weeks
  • Severe diabetic foot infection (soft tissue only): 2 to 4 weeks
  • Residual infected, but viable, bone: 4 to 6 weeks
  • No surgery or postoperative residual dead bone: 3 months or longer

Comment: Patients with diabetic foot infections should be started on parenteral treatment and should be switched to oral formulations when possible.

Uses:
  • Alternative treatment of infections following animal bites
  • Preemptive antimicrobial therapy to prevent infection in dog or cat bites
  • Alternative treatment for infected animal bite-related wounds caused by Pasteurella multocida
  • Empiric treatment of moderate or severe diabetic foot infections caused by methicillin-susceptible S aureus (MSSA), other Streptococcus species, Enterobacteriaceae, and/or obligate anaerobes

Usual Adult Dose for Skin and Structure Infection

Uncomplicated infections (bacteremia absent/unlikely): 1 gram IV every 6 to 8 hours
Moderately severe to severe infections: 1 gram IV every 4 hours OR 2 grams IV every 6 to 8 hours
Infections needing high-doses: 2 grams IV every 4 hours OR 3 grams IV every 6 hours
Duration of therapy: At least 10 days (group A beta-hemolytic streptococcal infections)

Comments:

  • This drug may be given via IV injection over 3 to 5 minutes or via IV infusion.
  • Uncomplicated infections included cutaneous infections, pneumonia, and urinary tract infections.
  • High-dose infections include gas gangrene.
  • Surgical drainage should be performed in infections involving collections of pus.

Uses:
  • Treatment of bone and joint infections caused by Staphylococcus aureus (including penicillinase-producing strains)
  • Treatment of intraabdominal infections (e.g., intraabdominal abscess, peritonitis) caused by Bacteroides species (including Bacteroides fragilis), Clostridium species, Escherichia coli, and Klebsiella species
  • Treatment of lower respiratory tract infections (e.g., lung abscesses, pneumonia) caused by Bacteroides species, Escherichia coli, Haemophilus influenzae, Klebsiella species, other streptococci (excluding enterococci, e.g., Enterococcus faecalis/Streptococcus faecalis), S aureus (including penicillinase-producing strains), and Streptococcus pneumoniae
  • Treatment of skin and structure infections cause by Bacteroides species (including B fragilis), Clostridium species, E coli, Klebsiella species, Peptococcus niger, Peptostreptococcus species, Proteus mirabilis, S aureus (including penicillinase-producing strains), Staphylococcus epidermidis, Streptococcus pyogenes and other streptococci (excluding enterococci, e.g., E faecalis/S faecalis)
  • Treatment of urinary tract infections caused by E coli, Klebsiella species, Morganella morganii, P mirabilis, Proteus vulgaris, and Providencia species (including Providencia rettgeri)

Infectious Diseases Society of America (IDSA) Recommendations:
1 gram IV every 6 to 8 hours

Duration of therapy:
  • Bone/joint infection without residual infected tissue (e.g., postamputation): 2 to 5 days)
  • Moderate diabetic foot infection, including residual infected soft tissue (soft tissue only): 1 to 3 weeks
  • Severe diabetic foot infection (soft tissue only): 2 to 4 weeks
  • Residual infected, but viable, bone: 4 to 6 weeks
  • No surgery or postoperative residual dead bone: 3 months or longer

Comment: Patients with diabetic foot infections should be started on parenteral treatment and should be switched to oral formulations when possible.

Uses:
  • Alternative treatment of infections following animal bites
  • Preemptive antimicrobial therapy to prevent infection in dog or cat bites
  • Alternative treatment for infected animal bite-related wounds caused by Pasteurella multocida
  • Empiric treatment of moderate or severe diabetic foot infections caused by methicillin-susceptible S aureus (MSSA), other Streptococcus species, Enterobacteriaceae, and/or obligate anaerobes

Usual Adult Dose for Pelvic Inflammatory Disease

Uncomplicated infections (bacteremia absent/unlikely): 1 gram IV every 6 to 8 hours
Moderately severe to severe infections: 1 gram IV every 4 hours OR 2 grams IV every 6 to 8 hours
Infections needing high-doses: 2 grams IV every 4 hours OR 3 grams IV every 6 hours
Duration of therapy: At least 10 days (group A beta-hemolytic streptococcal infections)

Comments:

  • This drug may be given via IV injection over 3 to 5 minutes or via IV infusion.
  • This drug does not have activity against Chlamydia trachomatis.
  • Patients with pelvic inflammatory disease potentially caused by C trachomatis should be given appropriate anti-chlamydial therapy.
  • Surgical drainage should be performed in infections involving collections of pus.

Use: Treatment of gynecological infections (e.g., endometritis, pelvic cellulitis, pelvic inflammatory disease) caused by Bacteroides species (including B fragilis), Clostridium species, E coli, Neisseria gonorrhoeae (including penicillinase-producing strains), P niger, Peptostreptococcus species, and Streptococcus agalactiae

US Centers for Disease Control and Prevention (US CDC) Recommendations:
Parenteral Treatment: 2 grams IV every 6 hours PLUS IV/oral doxycycline and IV gentamicin
  • Duration of therapy: 14 days

Alternative IM/Oral Treatment: 2 grams IM ONCE PLUS probenecid orally ONCE PLUS doxycycline orally given 2 times a day
  • Duration of therapy: 14 days

Comments:
  • At least 24 hours of inpatient observation is recommended for patients with tubo-ovarian abscesses.
  • Daily doses have not been evaluated for treatment of this condition; however, it has been efficacious in analogous conditions.
  • Oral therapy may be initiated within 24 to 28 hours of clinical improvement.

Use: Recommended adjunctive treatment of pelvic inflammatory disease due to C trachomatis, N gonorrhoeae, or Mycoplasma hominis

Usual Adult Dose for Endometritis

Uncomplicated infections (bacteremia absent/unlikely): 1 gram IV every 6 to 8 hours
Moderately severe to severe infections: 1 gram IV every 4 hours OR 2 grams IV every 6 to 8 hours
Infections needing high-doses: 2 grams IV every 4 hours OR 3 grams IV every 6 hours
Duration of therapy: At least 10 days (group A beta-hemolytic streptococcal infections)

Comments:

  • This drug may be given via IV injection over 3 to 5 minutes or via IV infusion.
  • This drug does not have activity against Chlamydia trachomatis.
  • Patients with pelvic inflammatory disease potentially caused by C trachomatis should be given appropriate anti-chlamydial therapy.
  • Surgical drainage should be performed in infections involving collections of pus.

Use: Treatment of gynecological infections (e.g., endometritis, pelvic cellulitis, pelvic inflammatory disease) caused by Bacteroides species (including B fragilis), Clostridium species, E coli, Neisseria gonorrhoeae (including penicillinase-producing strains), P niger, Peptostreptococcus species, and Streptococcus agalactiae

US Centers for Disease Control and Prevention (US CDC) Recommendations:
Parenteral Treatment: 2 grams IV every 6 hours PLUS IV/oral doxycycline and IV gentamicin
  • Duration of therapy: 14 days

Alternative IM/Oral Treatment: 2 grams IM ONCE PLUS probenecid orally ONCE PLUS doxycycline orally given 2 times a day
  • Duration of therapy: 14 days

Comments:
  • At least 24 hours of inpatient observation is recommended for patients with tubo-ovarian abscesses.
  • Daily doses have not been evaluated for treatment of this condition; however, it has been efficacious in analogous conditions.
  • Oral therapy may be initiated within 24 to 28 hours of clinical improvement.

Use: Recommended adjunctive treatment of pelvic inflammatory disease due to C trachomatis, N gonorrhoeae, or Mycoplasma hominis

Usual Adult Dose for Septicemia

Moderately severe to severe infections: 1 gram IV every 4 hours OR 2 grams IV every 6 to 8 hours
Infections needing high-doses: 2 grams IV every 4 hours OR 3 grams IV every 6 hours
Duration of therapy: At least 10 days (group A beta-hemolytic streptococcal infections)

Comments:

  • This drug may be given via IV injection over 3 to 5 minutes or via IV infusion.
  • Surgical drainage should be performed in infections involving collections of pus.

Use: Treatment of septicemia caused by Bacteroides species (including B fragilis), E coli, Klebsiella species, S aureus (including penicillinase-producing strains), and S pneumoniae

Usual Adult Dose for Cesarean Section

Single-dose regimen: 2 grams IV ONCE as soon as the umbilical cord is clamped

3-dose regimen: 2 grams IV every 4 hours for 3 doses, given as soon as the umbilical cord is clamped, then at 4 and 8 hours after the initial dose

Comment: This drug may be given via IV injection over 3 to 5 minutes or via IV infusion.

Use: Prophylaxis of infection in patients undergoing cesarean section

Usual Adult Dose for Surgical Prophylaxis

2 grams IV 30 to 60 minutes prior to surgery, followed by 2 grams every 6 hours after the first dose

  • Duration of therapy: 24 hours

Comment: This drug may be given via IV injection over 3 to 5 minutes or via IV infusion.

Use: Prophylaxis of infection in patients undergoing abdominal hysterectomy uncontaminated gastrointestinal surgery, or vaginal hysterectomy

American Society of Health-System Pharmacists (ASHP), IDSA, Society for Healthcare Epidemiology of America (SHEA), and Surgical Infection Society (SIS) Recommendations:
2 grams IV ONCE

Comment: The recommended redosing interval from the initiation of the preoperative dose is 2 hours.

Uses:
Recommended agent for surgical prophylaxis in patients who are undergoing the following procedures:
  • Appendectomy for uncomplicated appendicitis
  • Biliary tract (e.g., elective high-risk, open procedure)
  • Colorectal
  • Hysterectomy (abdominal/vaginal)
  • Small intestine (e.g., obstructed)
  • Some urologic procedures (e.g., clean-contaminated with entry into urinary tract)

Alternative agent for surgical prophylaxis in patients who are undergoing the following procedures:
  • Open biliary tract procedures

Adjunctive agent (with metronidazole) for surgical prophylaxis in patients who are undergoing colon procedures

Usual Adult Dose for Gonococcal Infection - Uncomplicated

US CDC recommendations:
Uncomplicated anorectal and urogenital gonococcal infections: 2 grams IM ONCE plus probenecid

Comments:

  • This regimen with probenecid is recommended if ceftriaxone is not an option.
  • Doxycycline therapy for 7 days (if not pregnant) or single dose azithromycin is also recommended to treat possible concurrent chlamydial infection.
  • The patient's sexual partner(s) should also be evaluated/treated.

Use: Treatment of uncomplicated gonococcal infections of the cervix, urethra, and rectum caused by N gonorrhoeae

Usual Pediatric Dose for Intraabdominal Infection

3 months and older: 80 to 160 mg/kg IV per day, given in 4 to 6 equal doses

  • Maximum dose: 12 grams/day
  • Duration of therapy: At least 10 days (group A beta-hemolytic streptococcal infections)

Comments:
  • This drug may be given via IV injection over 3 to 5 minutes or via IV infusion.
  • Higher doses should be used to treat severe or serious infections.
  • Surgical drainage should be performed in infections involving collections of pus.

Uses:
  • Treatment of bone and joint infections caused by S aureus (including penicillinase-producing strains)
  • Treatment of intraabdominal infections (e.g., intraabdominal abscess, peritonitis) caused by Bacteroides species (including B fragilis), Clostridium species, E coli, and Klebsiella species
  • Treatment of lower respiratory tract infections (e.g., lung abscesses, pneumonia) caused by Bacteroides species, E coli, H influenzae, Klebsiella species, other streptococci (excluding enterococci, e.g., E faecalis/S faecalis), S aureus (including penicillinase-producing strains), and S pneumoniae
  • Treatment of septicemia caused by Bacteroides species (including B fragilis), E coli, Klebsiella species, S aureus (including penicillinase-producing strains), and S pneumoniae
  • Treatment of skin and structure infections cause by Bacteroides species (including B fragilis), Clostridium species, E coli, Klebsiella species, P niger, Peptostreptococcus species, P mirabilis, S aureus (including penicillinase-producing strains), S epidermidis, S pyogenes and other streptococci (excluding enterococci, e.g., E faecalis/S faecalis)
  • Treatment of urinary tract infections caused by Escherichia coli, Klebsiella species, M morganii, P mirabilis, P vulgaris, and Providencia species (including Providencia rettgeri)

American Academy of Pediatrics (AAP) Recommendations:
Gestational age less than 32 weeks:
Postnatal age (PNA) 7 days or less: 35 mg/kg IV OR IM every 12 hours
PNA over 72 years: 35 mg/kg IV OR IM every 8 hours

Gestational age 32 weeks and older: 35 mg/kg IV OR IM every 8 hours

Pediatric patients beyond the newborn period: 80 to 160 mg/kg IV OR IM per day, given in divided doses 3 to 4 times a day
  • Maximum dose: 12 grams/day

Neonates (72 hours) or older: 40 mg/kg IV ONCE with/without IV gentamicin
  • Maximum dose: 3 grams/dose

Uses:
  • Treatment of ruptured viscus in traumatic wounds caused by enteric gram-negative bacilli, Clostridium species, enterococci, and/or anaerobes (Bacteroides species)
  • Treatment of ruptured viscus via colorectal or appendectomy caused by enteric gram-negative bacilli, Clostridium species, enterococci, and/or anaerobes (Bacteroides species)

International Society for Peritoneal Dialysis (ISPD) Recommendations:
PROPHYLAXIS: 30 to 40 mg/kg IV ONCE
  • Maximum dose: 2 grams/dose

Comment: Empirical doses should be given just prior to the procedure.

Uses:
  • Preferred empirical treatment for other gastrointestinal or genitourinary procedures in patients undergoing peritoneal dialysis
  • Treatment of peritonitis

Usual Pediatric Dose for Joint Infection

3 months and older: 80 to 160 mg/kg IV per day, given in 4 to 6 equal doses

  • Maximum dose: 12 grams/day
  • Duration of therapy: At least 10 days (group A beta-hemolytic streptococcal infections)

Comments:
  • This drug may be given via IV injection over 3 to 5 minutes or via IV infusion.
  • Higher doses should be used to treat severe or serious infections.
  • Surgical drainage should be performed in infections involving collections of pus.

Uses:
  • Treatment of bone and joint infections caused by S aureus (including penicillinase-producing strains)
  • Treatment of intraabdominal infections (e.g., intraabdominal abscess, peritonitis) caused by Bacteroides species (including B fragilis), Clostridium species, E coli, and Klebsiella species
  • Treatment of lower respiratory tract infections (e.g., lung abscesses, pneumonia) caused by Bacteroides species, E coli, H influenzae, Klebsiella species, other streptococci (excluding enterococci, e.g., E faecalis/S faecalis), S aureus (including penicillinase-producing strains), and S pneumoniae
  • Treatment of septicemia caused by Bacteroides species (including B fragilis), E coli, Klebsiella species, S aureus (including penicillinase-producing strains), and S pneumoniae
  • Treatment of skin and structure infections cause by Bacteroides species (including B fragilis), Clostridium species, E coli, Klebsiella species, P niger, Peptostreptococcus species, P mirabilis, S aureus (including penicillinase-producing strains), S epidermidis, S pyogenes and other streptococci (excluding enterococci, e.g., E faecalis/S faecalis)
  • Treatment of urinary tract infections caused by Escherichia coli, Klebsiella species, M morganii, P mirabilis, P vulgaris, and Providencia species (including Providencia rettgeri)

American Academy of Pediatrics (AAP) Recommendations:
Gestational age less than 32 weeks:
Postnatal age (PNA) 7 days or less: 35 mg/kg IV OR IM every 12 hours
PNA over 72 years: 35 mg/kg IV OR IM every 8 hours

Gestational age 32 weeks and older: 35 mg/kg IV OR IM every 8 hours

Pediatric patients beyond the newborn period: 80 to 160 mg/kg IV OR IM per day, given in divided doses 3 to 4 times a day
  • Maximum dose: 12 grams/day

Neonates (72 hours) or older: 40 mg/kg IV ONCE with/without IV gentamicin
  • Maximum dose: 3 grams/dose

Uses:
  • Treatment of ruptured viscus in traumatic wounds caused by enteric gram-negative bacilli, Clostridium species, enterococci, and/or anaerobes (Bacteroides species)
  • Treatment of ruptured viscus via colorectal or appendectomy caused by enteric gram-negative bacilli, Clostridium species, enterococci, and/or anaerobes (Bacteroides species)

International Society for Peritoneal Dialysis (ISPD) Recommendations:
PROPHYLAXIS: 30 to 40 mg/kg IV ONCE
  • Maximum dose: 2 grams/dose

Comment: Empirical doses should be given just prior to the procedure.

Uses:
  • Preferred empirical treatment for other gastrointestinal or genitourinary procedures in patients undergoing peritoneal dialysis
  • Treatment of peritonitis

Usual Pediatric Dose for Osteomyelitis

3 months and older: 80 to 160 mg/kg IV per day, given in 4 to 6 equal doses

  • Maximum dose: 12 grams/day
  • Duration of therapy: At least 10 days (group A beta-hemolytic streptococcal infections)

Comments:
  • This drug may be given via IV injection over 3 to 5 minutes or via IV infusion.
  • Higher doses should be used to treat severe or serious infections.
  • Surgical drainage should be performed in infections involving collections of pus.

Uses:
  • Treatment of bone and joint infections caused by S aureus (including penicillinase-producing strains)
  • Treatment of intraabdominal infections (e.g., intraabdominal abscess, peritonitis) caused by Bacteroides species (including B fragilis), Clostridium species, E coli, and Klebsiella species
  • Treatment of lower respiratory tract infections (e.g., lung abscesses, pneumonia) caused by Bacteroides species, E coli, H influenzae, Klebsiella species, other streptococci (excluding enterococci, e.g., E faecalis/S faecalis), S aureus (including penicillinase-producing strains), and S pneumoniae
  • Treatment of septicemia caused by Bacteroides species (including B fragilis), E coli, Klebsiella species, S aureus (including penicillinase-producing strains), and S pneumoniae
  • Treatment of skin and structure infections cause by Bacteroides species (including B fragilis), Clostridium species, E coli, Klebsiella species, P niger, Peptostreptococcus species, P mirabilis, S aureus (including penicillinase-producing strains), S epidermidis, S pyogenes and other streptococci (excluding enterococci, e.g., E faecalis/S faecalis)
  • Treatment of urinary tract infections caused by Escherichia coli, Klebsiella species, M morganii, P mirabilis, P vulgaris, and Providencia species (including Providencia rettgeri)

American Academy of Pediatrics (AAP) Recommendations:
Gestational age less than 32 weeks:
Postnatal age (PNA) 7 days or less: 35 mg/kg IV OR IM every 12 hours
PNA over 72 years: 35 mg/kg IV OR IM every 8 hours

Gestational age 32 weeks and older: 35 mg/kg IV OR IM every 8 hours

Pediatric patients beyond the newborn period: 80 to 160 mg/kg IV OR IM per day, given in divided doses 3 to 4 times a day
  • Maximum dose: 12 grams/day

Neonates (72 hours) or older: 40 mg/kg IV ONCE with/without IV gentamicin
  • Maximum dose: 3 grams/dose

Uses:
  • Treatment of ruptured viscus in traumatic wounds caused by enteric gram-negative bacilli, Clostridium species, enterococci, and/or anaerobes (Bacteroides species)
  • Treatment of ruptured viscus via colorectal or appendectomy caused by enteric gram-negative bacilli, Clostridium species, enterococci, and/or anaerobes (Bacteroides species)

International Society for Peritoneal Dialysis (ISPD) Recommendations:
PROPHYLAXIS: 30 to 40 mg/kg IV ONCE
  • Maximum dose: 2 grams/dose

Comment: Empirical doses should be given just prior to the procedure.

Uses:
  • Preferred empirical treatment for other gastrointestinal or genitourinary procedures in patients undergoing peritoneal dialysis
  • Treatment of peritonitis

Usual Pediatric Dose for Peritonitis

3 months and older: 80 to 160 mg/kg IV per day, given in 4 to 6 equal doses

  • Maximum dose: 12 grams/day
  • Duration of therapy: At least 10 days (group A beta-hemolytic streptococcal infections)

Comments:
  • This drug may be given via IV injection over 3 to 5 minutes or via IV infusion.
  • Higher doses should be used to treat severe or serious infections.
  • Surgical drainage should be performed in infections involving collections of pus.

Uses:
  • Treatment of bone and joint infections caused by S aureus (including penicillinase-producing strains)
  • Treatment of intraabdominal infections (e.g., intraabdominal abscess, peritonitis) caused by Bacteroides species (including B fragilis), Clostridium species, E coli, and Klebsiella species
  • Treatment of lower respiratory tract infections (e.g., lung abscesses, pneumonia) caused by Bacteroides species, E coli, H influenzae, Klebsiella species, other streptococci (excluding enterococci, e.g., E faecalis/S faecalis), S aureus (including penicillinase-producing strains), and S pneumoniae
  • Treatment of septicemia caused by Bacteroides species (including B fragilis), E coli, Klebsiella species, S aureus (including penicillinase-producing strains), and S pneumoniae
  • Treatment of skin and structure infections cause by Bacteroides species (including B fragilis), Clostridium species, E coli, Klebsiella species, P niger, Peptostreptococcus species, P mirabilis, S aureus (including penicillinase-producing strains), S epidermidis, S pyogenes and other streptococci (excluding enterococci, e.g., E faecalis/S faecalis)
  • Treatment of urinary tract infections caused by Escherichia coli, Klebsiella species, M morganii, P mirabilis, P vulgaris, and Providencia species (including Providencia rettgeri)

American Academy of Pediatrics (AAP) Recommendations:
Gestational age less than 32 weeks:
Postnatal age (PNA) 7 days or less: 35 mg/kg IV OR IM every 12 hours
PNA over 72 years: 35 mg/kg IV OR IM every 8 hours

Gestational age 32 weeks and older: 35 mg/kg IV OR IM every 8 hours

Pediatric patients beyond the newborn period: 80 to 160 mg/kg IV OR IM per day, given in divided doses 3 to 4 times a day
  • Maximum dose: 12 grams/day

Neonates (72 hours) or older: 40 mg/kg IV ONCE with/without IV gentamicin
  • Maximum dose: 3 grams/dose

Uses:
  • Treatment of ruptured viscus in traumatic wounds caused by enteric gram-negative bacilli, Clostridium species, enterococci, and/or anaerobes (Bacteroides species)
  • Treatment of ruptured viscus via colorectal or appendectomy caused by enteric gram-negative bacilli, Clostridium species, enterococci, and/or anaerobes (Bacteroides species)

International Society for Peritoneal Dialysis (ISPD) Recommendations:
PROPHYLAXIS: 30 to 40 mg/kg IV ONCE
  • Maximum dose: 2 grams/dose

Comment: Empirical doses should be given just prior to the procedure.

Uses:
  • Preferred empirical treatment for other gastrointestinal or genitourinary procedures in patients undergoing peritoneal dialysis
  • Treatment of peritonitis

Usual Pediatric Dose for Pneumonia

3 months and older: 80 to 160 mg/kg IV per day, given in 4 to 6 equal doses

  • Maximum dose: 12 grams/day
  • Duration of therapy: At least 10 days (group A beta-hemolytic streptococcal infections)

Comments:
  • This drug may be given via IV injection over 3 to 5 minutes or via IV infusion.
  • Higher doses should be used to treat severe or serious infections.
  • Surgical drainage should be performed in infections involving collections of pus.

Uses:
  • Treatment of bone and joint infections caused by S aureus (including penicillinase-producing strains)
  • Treatment of intraabdominal infections (e.g., intraabdominal abscess, peritonitis) caused by Bacteroides species (including B fragilis), Clostridium species, E coli, and Klebsiella species
  • Treatment of lower respiratory tract infections (e.g., lung abscesses, pneumonia) caused by Bacteroides species, E coli, H influenzae, Klebsiella species, other streptococci (excluding enterococci, e.g., E faecalis/S faecalis), S aureus (including penicillinase-producing strains), and S pneumoniae
  • Treatment of septicemia caused by Bacteroides species (including B fragilis), E coli, Klebsiella species, S aureus (including penicillinase-producing strains), and S pneumoniae
  • Treatment of skin and structure infections cause by Bacteroides species (including B fragilis), Clostridium species, E coli, Klebsiella species, P niger, Peptostreptococcus species, P mirabilis, S aureus (including penicillinase-producing strains), S epidermidis, S pyogenes and other streptococci (excluding enterococci, e.g., E faecalis/S faecalis)
  • Treatment of urinary tract infections caused by Escherichia coli, Klebsiella species, M morganii, P mirabilis, P vulgaris, and Providencia species (including Providencia rettgeri)

American Academy of Pediatrics (AAP) Recommendations:
Gestational age less than 32 weeks:
Postnatal age (PNA) 7 days or less: 35 mg/kg IV OR IM every 12 hours
PNA over 72 years: 35 mg/kg IV OR IM every 8 hours

Gestational age 32 weeks and older: 35 mg/kg IV OR IM every 8 hours

Pediatric patients beyond the newborn period: 80 to 160 mg/kg IV OR IM per day, given in divided doses 3 to 4 times a day
  • Maximum dose: 12 grams/day

Neonates (72 hours) or older: 40 mg/kg IV ONCE with/without IV gentamicin
  • Maximum dose: 3 grams/dose

Uses:
  • Treatment of ruptured viscus in traumatic wounds caused by enteric gram-negative bacilli, Clostridium species, enterococci, and/or anaerobes (Bacteroides species)
  • Treatment of ruptured viscus via colorectal or appendectomy caused by enteric gram-negative bacilli, Clostridium species, enterococci, and/or anaerobes (Bacteroides species)

International Society for Peritoneal Dialysis (ISPD) Recommendations:
PROPHYLAXIS: 30 to 40 mg/kg IV ONCE
  • Maximum dose: 2 grams/dose

Comment: Empirical doses should be given just prior to the procedure.

Uses:
  • Preferred empirical treatment for other gastrointestinal or genitourinary procedures in patients undergoing peritoneal dialysis
  • Treatment of peritonitis

Usual Pediatric Dose for Septicemia

3 months and older: 80 to 160 mg/kg IV per day, given in 4 to 6 equal doses

  • Maximum dose: 12 grams/day
  • Duration of therapy: At least 10 days (group A beta-hemolytic streptococcal infections)

Comments:
  • This drug may be given via IV injection over 3 to 5 minutes or via IV infusion.
  • Higher doses should be used to treat severe or serious infections.
  • Surgical drainage should be performed in infections involving collections of pus.

Uses:
  • Treatment of bone and joint infections caused by S aureus (including penicillinase-producing strains)
  • Treatment of intraabdominal infections (e.g., intraabdominal abscess, peritonitis) caused by Bacteroides species (including B fragilis), Clostridium species, E coli, and Klebsiella species
  • Treatment of lower respiratory tract infections (e.g., lung abscesses, pneumonia) caused by Bacteroides species, E coli, H influenzae, Klebsiella species, other streptococci (excluding enterococci, e.g., E faecalis/S faecalis), S aureus (including penicillinase-producing strains), and S pneumoniae
  • Treatment of septicemia caused by Bacteroides species (including B fragilis), E coli, Klebsiella species, S aureus (including penicillinase-producing strains), and S pneumoniae
  • Treatment of skin and structure infections cause by Bacteroides species (including B fragilis), Clostridium species, E coli, Klebsiella species, P niger, Peptostreptococcus species, P mirabilis, S aureus (including penicillinase-producing strains), S epidermidis, S pyogenes and other streptococci (excluding enterococci, e.g., E faecalis/S faecalis)
  • Treatment of urinary tract infections caused by Escherichia coli, Klebsiella species, M morganii, P mirabilis, P vulgaris, and Providencia species (including Providencia rettgeri)

American Academy of Pediatrics (AAP) Recommendations:
Gestational age less than 32 weeks:
Postnatal age (PNA) 7 days or less: 35 mg/kg IV OR IM every 12 hours
PNA over 72 years: 35 mg/kg IV OR IM every 8 hours

Gestational age 32 weeks and older: 35 mg/kg IV OR IM every 8 hours

Pediatric patients beyond the newborn period: 80 to 160 mg/kg IV OR IM per day, given in divided doses 3 to 4 times a day
  • Maximum dose: 12 grams/day

Neonates (72 hours) or older: 40 mg/kg IV ONCE with/without IV gentamicin
  • Maximum dose: 3 grams/dose

Uses:
  • Treatment of ruptured viscus in traumatic wounds caused by enteric gram-negative bacilli, Clostridium species, enterococci, and/or anaerobes (Bacteroides species)
  • Treatment of ruptured viscus via colorectal or appendectomy caused by enteric gram-negative bacilli, Clostridium species, enterococci, and/or anaerobes (Bacteroides species)

International Society for Peritoneal Dialysis (ISPD) Recommendations:
PROPHYLAXIS: 30 to 40 mg/kg IV ONCE
  • Maximum dose: 2 grams/dose

Comment: Empirical doses should be given just prior to the procedure.

Uses:
  • Preferred empirical treatment for other gastrointestinal or genitourinary procedures in patients undergoing peritoneal dialysis
  • Treatment of peritonitis

Usual Pediatric Dose for Bacterial Infection

3 months and older: 80 to 160 mg/kg IV per day, given in 4 to 6 equal doses

  • Maximum dose: 12 grams/day
  • Duration of therapy: At least 10 days (group A beta-hemolytic streptococcal infections)

Comments:
  • This drug may be given via IV injection over 3 to 5 minutes or via IV infusion.
  • Higher doses should be used to treat severe or serious infections.
  • Surgical drainage should be performed in infections involving collections of pus.

Uses:
  • Treatment of bone and joint infections caused by S aureus (including penicillinase-producing strains)
  • Treatment of intraabdominal infections (e.g., intraabdominal abscess, peritonitis) caused by Bacteroides species (including B fragilis), Clostridium species, E coli, and Klebsiella species
  • Treatment of lower respiratory tract infections (e.g., lung abscesses, pneumonia) caused by Bacteroides species, E coli, H influenzae, Klebsiella species, other streptococci (excluding enterococci, e.g., E faecalis/S faecalis), S aureus (including penicillinase-producing strains), and S pneumoniae
  • Treatment of septicemia caused by Bacteroides species (including B fragilis), E coli, Klebsiella species, S aureus (including penicillinase-producing strains), and S pneumoniae
  • Treatment of skin and structure infections cause by Bacteroides species (including B fragilis), Clostridium species, E coli, Klebsiella species, P niger, Peptostreptococcus species, P mirabilis, S aureus (including penicillinase-producing strains), S epidermidis, S pyogenes and other streptococci (excluding enterococci, e.g., E faecalis/S faecalis)
  • Treatment of urinary tract infections caused by Escherichia coli, Klebsiella species, M morganii, P mirabilis, P vulgaris, and Providencia species (including Providencia rettgeri)

American Academy of Pediatrics (AAP) Recommendations:
Gestational age less than 32 weeks:
Postnatal age (PNA) 7 days or less: 35 mg/kg IV OR IM every 12 hours
PNA over 72 years: 35 mg/kg IV OR IM every 8 hours

Gestational age 32 weeks and older: 35 mg/kg IV OR IM every 8 hours

Pediatric patients beyond the newborn period: 80 to 160 mg/kg IV OR IM per day, given in divided doses 3 to 4 times a day
  • Maximum dose: 12 grams/day

Neonates (72 hours) or older: 40 mg/kg IV ONCE with/without IV gentamicin
  • Maximum dose: 3 grams/dose

Uses:
  • Treatment of ruptured viscus in traumatic wounds caused by enteric gram-negative bacilli, Clostridium species, enterococci, and/or anaerobes (Bacteroides species)
  • Treatment of ruptured viscus via colorectal or appendectomy caused by enteric gram-negative bacilli, Clostridium species, enterococci, and/or anaerobes (Bacteroides species)

International Society for Peritoneal Dialysis (ISPD) Recommendations:
PROPHYLAXIS: 30 to 40 mg/kg IV ONCE
  • Maximum dose: 2 grams/dose

Comment: Empirical doses should be given just prior to the procedure.

Uses:
  • Preferred empirical treatment for other gastrointestinal or genitourinary procedures in patients undergoing peritoneal dialysis
  • Treatment of peritonitis

Usual Pediatric Dose for Urinary Tract Infection

3 months and older: 80 to 160 mg/kg IV per day, given in 4 to 6 equal doses

  • Maximum dose: 12 grams/day
  • Duration of therapy: At least 10 days (group A beta-hemolytic streptococcal infections)

Comments:
  • This drug may be given via IV injection over 3 to 5 minutes or via IV infusion.
  • Higher doses should be used to treat severe or serious infections.
  • Surgical drainage should be performed in infections involving collections of pus.

Uses:
  • Treatment of bone and joint infections caused by S aureus (including penicillinase-producing strains)
  • Treatment of intraabdominal infections (e.g., intraabdominal abscess, peritonitis) caused by Bacteroides species (including B fragilis), Clostridium species, E coli, and Klebsiella species
  • Treatment of lower respiratory tract infections (e.g., lung abscesses, pneumonia) caused by Bacteroides species, E coli, H influenzae, Klebsiella species, other streptococci (excluding enterococci, e.g., E faecalis/S faecalis), S aureus (including penicillinase-producing strains), and S pneumoniae
  • Treatment of septicemia caused by Bacteroides species (including B fragilis), E coli, Klebsiella species, S aureus (including penicillinase-producing strains), and S pneumoniae
  • Treatment of skin and structure infections cause by Bacteroides species (including B fragilis), Clostridium species, E coli, Klebsiella species, P niger, Peptostreptococcus species, P mirabilis, S aureus (including penicillinase-producing strains), S epidermidis, S pyogenes and other streptococci (excluding enterococci, e.g., E faecalis/S faecalis)
  • Treatment of urinary tract infections caused by Escherichia coli, Klebsiella species, M morganii, P mirabilis, P vulgaris, and Providencia species (including Providencia rettgeri)

American Academy of Pediatrics (AAP) Recommendations:
Gestational age less than 32 weeks:
Postnatal age (PNA) 7 days or less: 35 mg/kg IV OR IM every 12 hours
PNA over 72 years: 35 mg/kg IV OR IM every 8 hours

Gestational age 32 weeks and older: 35 mg/kg IV OR IM every 8 hours

Pediatric patients beyond the newborn period: 80 to 160 mg/kg IV OR IM per day, given in divided doses 3 to 4 times a day
  • Maximum dose: 12 grams/day

Neonates (72 hours) or older: 40 mg/kg IV ONCE with/without IV gentamicin
  • Maximum dose: 3 grams/dose

Uses:
  • Treatment of ruptured viscus in traumatic wounds caused by enteric gram-negative bacilli, Clostridium species, enterococci, and/or anaerobes (Bacteroides species)
  • Treatment of ruptured viscus via colorectal or appendectomy caused by enteric gram-negative bacilli, Clostridium species, enterococci, and/or anaerobes (Bacteroides species)

International Society for Peritoneal Dialysis (ISPD) Recommendations:
PROPHYLAXIS: 30 to 40 mg/kg IV ONCE
  • Maximum dose: 2 grams/dose

Comment: Empirical doses should be given just prior to the procedure.

Uses:
  • Preferred empirical treatment for other gastrointestinal or genitourinary procedures in patients undergoing peritoneal dialysis
  • Treatment of peritonitis

Usual Pediatric Dose for Skin and Structure Infection

3 months and older: 80 to 160 mg/kg IV per day, given in 4 to 6 equal doses

  • Maximum dose: 12 grams/day
  • Duration of therapy: At least 10 days (group A beta-hemolytic streptococcal infections)

Comments:
  • This drug may be given via IV injection over 3 to 5 minutes or via IV infusion.
  • Higher doses should be used to treat severe or serious infections.
  • Surgical drainage should be performed in infections involving collections of pus.

Uses:
  • Treatment of bone and joint infections caused by S aureus (including penicillinase-producing strains)
  • Treatment of intraabdominal infections (e.g., intraabdominal abscess, peritonitis) caused by Bacteroides species (including B fragilis), Clostridium species, E coli, and Klebsiella species
  • Treatment of lower respiratory tract infections (e.g., lung abscesses, pneumonia) caused by Bacteroides species, E coli, H influenzae, Klebsiella species, other streptococci (excluding enterococci, e.g., E faecalis/S faecalis), S aureus (including penicillinase-producing strains), and S pneumoniae
  • Treatment of septicemia caused by Bacteroides species (including B fragilis), E coli, Klebsiella species, S aureus (including penicillinase-producing strains), and S pneumoniae
  • Treatment of skin and structure infections cause by Bacteroides species (including B fragilis), Clostridium species, E coli, Klebsiella species, P niger, Peptostreptococcus species, P mirabilis, S aureus (including penicillinase-producing strains), S epidermidis, S pyogenes and other streptococci (excluding enterococci, e.g., E faecalis/S faecalis)
  • Treatment of urinary tract infections caused by Escherichia coli, Klebsiella species, M morganii, P mirabilis, P vulgaris, and Providencia species (including Providencia rettgeri)

American Academy of Pediatrics (AAP) Recommendations:
Gestational age less than 32 weeks:
Postnatal age (PNA) 7 days or less: 35 mg/kg IV OR IM every 12 hours
PNA over 72 years: 35 mg/kg IV OR IM every 8 hours

Gestational age 32 weeks and older: 35 mg/kg IV OR IM every 8 hours

Pediatric patients beyond the newborn period: 80 to 160 mg/kg IV OR IM per day, given in divided doses 3 to 4 times a day
  • Maximum dose: 12 grams/day

Neonates (72 hours) or older: 40 mg/kg IV ONCE with/without IV gentamicin
  • Maximum dose: 3 grams/dose

Uses:
  • Treatment of ruptured viscus in traumatic wounds caused by enteric gram-negative bacilli, Clostridium species, enterococci, and/or anaerobes (Bacteroides species)
  • Treatment of ruptured viscus via colorectal or appendectomy caused by enteric gram-negative bacilli, Clostridium species, enterococci, and/or anaerobes (Bacteroides species)

International Society for Peritoneal Dialysis (ISPD) Recommendations:
PROPHYLAXIS: 30 to 40 mg/kg IV ONCE
  • Maximum dose: 2 grams/dose

Comment: Empirical doses should be given just prior to the procedure.

Uses:
  • Preferred empirical treatment for other gastrointestinal or genitourinary procedures in patients undergoing peritoneal dialysis
  • Treatment of peritonitis

Usual Pediatric Dose for Pelvic Inflammatory Disease

3 months and older: 80 to 160 mg/kg IV per day, given in 4 to 6 equal doses

  • Maximum dose: 12 grams/day
  • Duration of therapy: At least 10 days (group A beta-hemolytic streptococcal infections)

Comments:
  • This drug may be given via IV injection over 3 to 5 minutes or via IV infusion.
  • This drug does not have activity against C trachomatis.
  • Patients with pelvic inflammatory disease potentially caused by C trachomatis should be given appropriate anti-chlamydial therapy.
  • Surgical drainage should be performed in infections involving collections of pus.

Use: Treatment of gynecological infections (e.g., endometritis, pelvic cellulitis, pelvic inflammatory disease) caused by Bacteroides species (including B fragilis), Clostridium species, E coli, N gonorrhoeae (including penicillinase-producing strains), P niger, Peptostreptococcus species, and S agalactiae

US CDC Recommendations:
Parenteral Treatment: 2 grams IV every 6 hours PLUS IV/oral doxycycline and IV gentamicin
  • Duration of therapy: 14 days

Alternative IM/Oral Treatment: 2 grams IM ONCE PLUS probenecid orally ONCE PLUS doxycycline orally given 2 times a day
  • Duration of therapy: 14 days

Comments:
  • At least 24 hours of inpatient observation is recommended for patients with tubo-ovarian abscesses.
  • Daily doses have not been evaluated for treatment of this condition; however, it has been efficacious in analogous conditions.
  • Oral therapy may be initiated within 24 to 28 hours of clinical improvement.

Use: Recommended adjunctive treatment of pelvic inflammatory disease due to C trachomatis, N gonorrhoeae, or M hominis

Usual Pediatric Dose for Endometritis

3 months and older: 80 to 160 mg/kg IV per day, given in 4 to 6 equal doses

  • Maximum dose: 12 grams/day
  • Duration of therapy: At least 10 days (group A beta-hemolytic streptococcal infections)

Comments:
  • This drug may be given via IV injection over 3 to 5 minutes or via IV infusion.
  • This drug does not have activity against C trachomatis.
  • Patients with pelvic inflammatory disease potentially caused by C trachomatis should be given appropriate anti-chlamydial therapy.
  • Surgical drainage should be performed in infections involving collections of pus.

Use: Treatment of gynecological infections (e.g., endometritis, pelvic cellulitis, pelvic inflammatory disease) caused by Bacteroides species (including B fragilis), Clostridium species, E coli, N gonorrhoeae (including penicillinase-producing strains), P niger, Peptostreptococcus species, and S agalactiae

US CDC Recommendations:
Parenteral Treatment: 2 grams IV every 6 hours PLUS IV/oral doxycycline and IV gentamicin
  • Duration of therapy: 14 days

Alternative IM/Oral Treatment: 2 grams IM ONCE PLUS probenecid orally ONCE PLUS doxycycline orally given 2 times a day
  • Duration of therapy: 14 days

Comments:
  • At least 24 hours of inpatient observation is recommended for patients with tubo-ovarian abscesses.
  • Daily doses have not been evaluated for treatment of this condition; however, it has been efficacious in analogous conditions.
  • Oral therapy may be initiated within 24 to 28 hours of clinical improvement.

Use: Recommended adjunctive treatment of pelvic inflammatory disease due to C trachomatis, N gonorrhoeae, or M hominis

Usual Pediatric Dose for Surgical Prophylaxis

3 months and older: 30 to 40 mg/kg IV 30 to 60 minutes prior to surgery, followed by 30 to 40 mg/kg every 6 hours after the first dose

  • Duration of therapy: 24 hours

Comment: This drug may be given via IV injection over 3 to 5 minutes or via IV infusion.

Use: Prophylaxis of infection in patients undergoing abdominal hysterectomy uncontaminated gastrointestinal surgery, or vaginal hysterectomy

AAP Recommendations:
Neonates (72 hours) or older: 40 mg/kg IV ONCE PLUS IV gentamicin
  • Maximum dose: 3 grams/dose

Use: Preoperative antimicrobial prophylaxis in neonatal patients older than 72 hours and children undergoing uncomplicated, nonperforated colorectal or appendectomy with the following likely pathogens: enteric gram-negative bacilli, enterococci, and/or anaerobes (Bacteroides species)

ASHP, IDSA, SHEA, and SIS Recommendations:
40 mg/kg IV ONCE
  • Maximum dose: 2 grams/dose

Comment: The recommended redosing interval from the initiation of the preoperative dose is 2 hours.

Uses:
Recommended agent for surgical prophylaxis in patients who are undergoing the following procedures:
  • Appendectomy for uncomplicated appendicitis
  • Biliary tract (e.g., elective high-risk, open procedure)
  • Colorectal
  • Hysterectomy (abdominal/vaginal)
  • Small intestine (e.g., obstructed)
  • Some urologic procedures (e.g., clean-contaminated with entry into urinary tract)

Alternative agent for surgical prophylaxis in patients who are undergoing the following procedures:
  • Open biliary tract procedures

Adjunctive agent (with metronidazole) for surgical prophylaxis in patients who are undergoing colon procedures

Usual Pediatric Dose for Cesarean Section

Single-dose regimen: 2 grams IV ONCE as soon as the umbilical cord is clamped

3-dose regimen: 2 grams IV every 4 hours for 3 doses, given as soon as the umbilical cord is clamped, then at 4 and 8 hours after the initial dose

Comment: This drug may be given via IV injection over 3 to 5 minutes or via IV infusion.

Use: Prophylaxis of infection in patients undergoing cesarean section

Usual Pediatric Dose for Gonococcal Infection - Uncomplicated

US CDC recommendations:
Uncomplicated anorectal and urogenital gonococcal infections in adolescents: 2 grams IM ONCE plus probenecid

Comments:

  • This regimen with probenecid is recommended if ceftriaxone is not an option.
  • Doxycycline therapy for 7 days (if not pregnant) or single dose azithromycin is also recommended to treat possible concurrent chlamydial infection.
  • The patient's sexual partner(s) should also be evaluated/treated.

Use: Treatment of uncomplicated gonococcal infections of the cervix, urethra, and rectum caused by N gonorrhoeae

Renal Dose Adjustments

Pediatric:
3 months and older: Doses and frequencies should be adjusted consisted with adult renal dose adjustments.

Adults:
Loading dose: 1 to 2 grams via IV injection over 3 to 5 minutes ONCE

Maintenance dose:

  • Mild renal dysfunction (CrCl 30 to 50 mL/min): 1 to 2 grams over 3 to 5 minutes or IV infusion every 8 to 12 hours
  • Moderate renal dysfunction (CrCl 10 to 29 mL/min): 1 to 2 grams over 3 to 5 minutes or IV infusion every 12 to 24 hours
  • Severe renal dysfunction (CrCl 5 to 9 mL/min): 0.5 to 1 gram over 3 to 5 minutes or IV infusion every 12 to 48 hours
  • Essentially no renal function (CrCl less than 5 mL/min): 0.5 to 1 gram over 3 to 5 minutes or IV infusion every 24 to 48 hours

Liver Dose Adjustments

Data not available

Precautions

CONTRAINDICATIONS:

  • Hypersensitivity to the active component, the cephalosporin group of antibiotics, or to any of the ingredients

Safety and efficacy have not been established in patients younger than 3 months.

Consult WARNINGS section for additional precautions.

Dialysis

Hemodialysis:
Pediatric:
3 months and older: Doses and frequencies should be adjusted consistent with adult renal dose adjustments.

Adults:
Loading dose: 1 to 2 grams IV after each hemodialysis

Maintenance dose:

  • Mild renal dysfunction (CrCl 30 to 50 mL/min): 1 to 2 grams IV every 8 to 12 hours
  • Moderate renal dysfunction (CrCl 10 to 29 mL/min): 1 to 2 grams IV every 12 to 24 hours
  • Severe renal dysfunction (CrCl 5 to 9 mL/min): 0.5 to 1 gram IV every 12 to 48 hours
  • Essentially no renal function (CrCl less than 5 mL/min): 0.5 to 1 gram IV every 24 to 48 hours

Other Comments

Administration advice:

  • IM: This drug should be given deep into a large muscle (e.g., upper outer quadrant of the gluteus maximus, lateral thigh).
  • IV: This drug may be given via IV injection (over 3 to 5 minutes) OR infusion; intraarterial administration should be avoided.

Storage requirements:
  • The manufacturer product information should be consulted.

Reconstitution/preparation techniques:
  • The manufacturer product information should be consulted.

IV compatibility:
  • The manufacturer product information should be consulted.

General:
  • Local epidemiological and susceptibility patterns should be used to guide treatment selection in the absence of patient-specific culture and susceptibility information.
  • Some experts recommend against using this drug to treat meningitis.

Monitoring:
  • HEMATOLOGIC: Hematopoietic system function tests periodically, especially during prolonged treatment
  • HEPATIC: Liver function tests periodically, especially during prolonged treatment
  • RENAL: Renal function monitoring, especially regularly when used with aminoglycosides and periodically during prolonged treatment

Patient advice:
  • Advise patients to speak to their healthcare provider if they become pregnant, intend to become pregnant, or are breastfeeding.
  • Patients should be directed to take the full course of treatment, even if they feel better.
  • Patients should be instructed to report signs/symptoms of Clostridium difficile (e.g., watery/bloody stools, stomach cramps, fever), for up to 2 months after stopping treatment
Share this Article
Latest News
Medical News

Shingles vaccine may lower heart disease risk by up to 8 years

May 09, 2025
Obesity, unhealthy lifestyles may cause heart to age by 5–45 years
Aging: As little as 5 minutes of exercise may keep the brain healthy
Prostate cancer: Simple urine test may help with early detection
Cancer treatment side effects: Exercise may reduce pain, fatigue
Alzheimer's: Exercising in middle age may reduce beta-amyloid in brain...
Related Drugs
Fidanacogene Elaparvovec
Cerave Anti-Itch
Centrum Adult
Crovalimab
Cyltezo Prefilled Syringe
Zepbound Pen
Mylanta One
Uretron Ds
Medihoney Wound And Burn Dressing
Lidotrode

Other drugs

Name Drug Class Updated
Fidanacogene Elaparvovec Drugs 03-Oct-2024
Cerave Anti-Itch Drugs 02-Oct-2024
Centrum Adult Drugs 02-Oct-2024
Crovalimab Drugs 02-Oct-2024
Cyltezo Prefilled Syringe Drugs 01-Oct-2024
Zepbound Pen Drugs 30-Sep-2024
Mylanta One Drugs 27-Sep-2024
Uretron Ds Drugs 27-Sep-2024
Medihoney Wound And Burn Dressing Drugs 26-Sep-2024
Lidotrode Drugs 26-Sep-2024
Libervant Drugs 26-Sep-2024
Moderna Covid-19 Drugs 25-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024

Categories

  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health

About US

Welcome to TheMediTary.Com

Our website provides reliable and up-to-date information on various medical topics. We empower individuals to take charge of their health by simplifying complex medical jargon and providing practical tips and advice. We prioritize the privacy and confidentiality of our users and welcome feedback to improve our services.

Website use data of FDA and other sources

DMCA.com Protection Status Truste Protection Status Trust Mark Protection Status
HONcode logo We comply with the HONcode standard for trustworthy health information.
Quick Link
  • About Us
  • Contact Us
  • Editorial Policy
  • Privacy Policy
  • Accessibility Policy
  • Terms & Conditions
  • Disclaimer
  • DMCA
  • Do Not Sell My Personal Information
  • Sitemap
  • Care Notes
  • Health Guide
  • Professional
Drugs
  • New Drugs
  • Medical Answers
  • Drugs A-Z
  • Drug Classes
  • Drug Dosage
  • Pill Identifier
  • Consumer Infor
  • Side Effects
  • Inactive Ingredients
  • Pregnancy Warnings
  • Patient Tips
  • Treatments
News
  • Latest News
  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health
Find US
  • Medium
  • Google Site
  • Blogspot
  • API
  • Reddit
  • Tumblr
  • Scoop.it
  • Substack
  • Wordpress
  • Wix
  • Behance

© 2025 TheMediTary.Com All rights reserved. Operated by